A Womb Becomes an Operating Theatre: The Surgery That Could Change the – Good Machine

TL;DR

Baby Theo, now five months old, became the third baby in the world — and the first from the UK — to undergo pioneering in-utero surgery for complex gastroschisis, a condition where the intestines develop outside the body through an opening in the abdominal wall.
The surgery was performed at 26 weeks gestation at Texas Children's Hospital in Houston, led by Dr Michael Belfort, as part of a first-of-its-kind clinical trial in partnership with Great Ormond Street Hospital (GOSH) in London and KU Leuven in Belgium.
The procedure involved a Botox injection into the fetal abdominal wall (to relax muscles), followed by keyhole surgery through a partially exposed uterus. The amniotic fluid was drained and replaced with CO₂ gas to create operating space. The intestines were gently pushed back inside and the abdomen was stitched closed.
Theo was carried to full term and born by vaginal delivery in February. He left hospital after four days. His mother, Maisie Savage, described him as "a completely normal baby essentially."
The standard postnatal treatment for complex gastroschisis involves weeks to months in neonatal intensive care, multiple surgeries, IV feeding for up to two years, and a 10% mortality rate even with the highest level of care.

What Happened

Maisie Savage, 29, and Josh French, 36, both teachers from London, learned at their 20-week scan that their unborn baby had gastroschisis — a congenital abdominal wall defect where the belly button does not develop properly, causing the intestines to grow externally in the amniotic fluid. The condition affects roughly one in 3,000 babies in the UK each year, or about 200–300 babies annually.

At 24 weeks, specialists at Great Ormond Street Hospital determined that Theo had the more serious form: complex gastroschisis. In standard care, this diagnosis means up to six months in neonatal intensive care, multiple surgeries to gradually return the intestines to the abdomen, intravenous nutritional feeding for up to two years, and a possible intestinal transplant. Even with the highest level of care, one in 10 babies dies.

GOSH referred the family to Texas Children's Hospital in Houston, where Dr Michael Belfort — obstetrician and gynaecologist-in-chief — had been leading a clinical trial for in-utero repair of complex gastroschisis. Belfort had previously pioneered a similar in-utero surgical approach for spina bifida.

The trial protocol required a two-stage process. First, Maisie travelled to Leuven Hospital in Belgium, where specialists administered a Botox injection through her womb into Theo's abdominal wall. The botulinum toxin relaxed the abdominal muscles, making it possible to reposition the intestines without excessive pressure on the fetal abdomen.

The family then flew to Texas, where the main procedure was performed in November 2025 at 26 weeks gestation. Surgeons partially exposed Maisie's uterus, drained the amniotic fluid, and replaced it with carbon dioxide gas to expand the operating space. Using keyhole (fetoscopic) surgery, they gently pushed Theo's intestines back inside his abdominal cavity and stitched the opening closed.

The operation was a complete success. "The mother, the baby, the surgery, the time of the surgery, the fact that we had zero complications during the fetal surgery and after the fetal surgery — just remarkable," Belfort told the BBC.

Maisie carried Theo to full term. He was born by vaginal delivery in February 2026 in Texas. He left hospital after four days. Now five months old and back home in London, Theo is thriving. "Everything they did just completely reversed what could have been a really horrible start to his life," Maisie said. "He's just the best. He's a completely normal baby essentially."

Theo was the third baby worldwide to undergo the procedure. The clinical trial, formally registered as NCT05704257 and led by Baylor College of Medicine, aims to enrol 10 patients and evaluate safety and feasibility. Primary completion is expected by December 2029.

What It Actually Means

This is a story about what happens when a surgical technique proven in one domain — in-utero spina bifida repair — is adapted to a different condition by a team willing to treat the womb as a surgical space rather than a barrier.

The logic of in-utero repair for gastroschisis is compelling. When intestines are exposed to amniotic fluid for months, they become inflamed, damaged, and sometimes necrotic. The longer the exposure, the worse the outcome. Postnatal repair means the baby arrives with already-damaged intestines that must be gradually returned to an abdominal cavity that has not grown to accommodate them. The result is a long, painful, and uncertain recovery.

In-utero repair intervenes before the damage accumulates. The intestines are returned to the abdomen early in development. The abdominal wall is closed. The baby continues to grow in a protected environment. By the time of birth, the repair is complete — and the baby can go home in days rather than months.

The Botox innovation is particularly elegant. One of the challenges of returning intestines to the fetal abdomen is that the abdominal muscles are tight — there is not enough space. Botox relaxes those muscles temporarily, creating the space needed for the repair without damaging the tissue. It is a solution that is both simple and non-obvious — the hallmark of a genuine surgical innovation.

Professor Paolo De Coppi, paediatric surgeon at GOSH and part of the trial team, was direct about the implications: "Previous success rates with spina bifida indicate this could essentially offer a cure for gastroschisis. If the results are positive, we hope this could become the standard operation for complex gastroschisis cases."

That is a strong claim — "essentially a cure" — from a senior clinician at one of the world's leading children's hospitals. It reflects the magnitude of the difference between the standard postnatal pathway (months in NICU, multiple surgeries, 10% mortality) and the in-utero pathway (surgery at 26 weeks, full-term delivery, discharge in days).

The Evidence Bar

Three patients is not a trial. The clinical trial is designed to enrol 10, and the primary completion date is December 2029. We are years away from knowing whether the results are replicable, whether the safety profile holds across a larger cohort, and whether the procedure can be performed by surgical teams beyond Belfort's.

The risks are real. Fetal surgery carries risks of preterm labour, uterine rupture, infection, and fetal death. The inclusion criteria for the trial are strict: singleton pregnancy, no significant associated anomalies, gestational age between 20 and 27 weeks, and a support person available for the duration of the pregnancy. This is not a procedure that can be offered broadly without substantial infrastructure and expertise.

But the direction of travel is clear. The first three patients have had outcomes that are dramatically better than the standard postnatal pathway. If the trial continues to produce results like Theo's, the case for making in-utero repair the standard of care for complex gastroschisis will be difficult to resist.

Hype Deconstruction

What this isn't: This is not a proven treatment. Three patients, one surgical team, zero long-term follow-up data. The trial is in its earliest stages. The procedure is not available outside the trial. And it is not applicable to simple gastroschisis — only to the complex form, which represents a subset of cases.

What's genuinely new: The adaptation of in-utero surgical techniques from spina bifida to gastroschisis. The use of Botox as a pre-surgical muscle relaxant in a fetal context. The partnership model — Texas Children's, GOSH, and KU Leuven collaborating across three countries to offer a procedure that no single centre could develop alone.

Stakeholder Landscape

Expectant parents receiving a complex gastroschisis diagnosis are the primary stakeholders. The current standard of care is gruelling and uncertain. The prospect of a single in-utero procedure followed by a near-normal birth and recovery is transformative — if the trial results hold.
Fetal surgery centres face a build-or-refer decision. The procedure requires specialised equipment, surgical expertise, and multidisciplinary teams. Few centres worldwide can offer it. The trial's success would create pressure to expand capacity.
Neonatal intensive care units would see reduced demand for complex gastroschisis cases if in-utero repair becomes standard. The resource implications are significant — months of NICU care replaced by a single surgical procedure.
Health systems and insurers face a cost-benefit calculation. The upfront cost of in-utero surgery (including international travel for the trial model) is high. But the avoided cost of months of NICU care, multiple surgeries, and long-term nutritional support is likely higher. The economic case probably favours in-utero repair — but the data to prove it does not yet exist.
The broader field of fetal medicine gains a proof point. Belfort told the BBC: "The inside of the uterus is now a new surgical space for innovation. And spina bifida and gastroschisis are just two, but I believe that we could actually do certain cardiac surgeries in utero, and I think we can also do some lung surgeries in utero." The womb as operating theatre is a frontier that is just beginning to open.

Cross-Layer Implications

Medical training: In-utero surgery requires a combination of obstetric, fetal, and paediatric surgical skills that current training pathways do not produce. The workforce pipeline is a binding constraint on scaling.
Medical tourism and equity: The current trial requires families to travel internationally. If the procedure becomes standard, access will depend on geography, wealth, and the willingness of health systems to invest in fetal surgery centres. The equity implications are significant.
Regulatory: The trial is registered with the FDA (NCT05704257). Regulatory approval pathways for fetal surgical devices and procedures are less developed than for drugs. The trial itself is helping to define what regulatory standards should apply.

What This Means for You

If you or someone you know is facing a complex gastroschisis diagnosis: The trial at Texas Children's Hospital is recruiting. The inclusion criteria are strict. GOSH is the UK referral partner. The procedure is not available outside the trial. Ask your specialist about eligibility — but understand that this is experimental surgery with real risks.
If you are a clinician: The trial protocol is publicly available at ClinicalTrials.gov (NCT05704257). The two-stage Botox-plus-fetoscopic-repair model is the key innovation. Monitor for published results.
If you are a general reader: This is what medical progress looks like at the frontier — a small number of patients, an international collaboration, a surgical team willing to adapt techniques from one condition to another, and outcomes that are dramatically better than the standard of care. The evidence bar is not yet met. But the early results justify the attention.

Uncertainty Ledger

Sample size: Three patients. The trial aims for 10. Results from a single surgical team may not generalise.
Long-term outcomes: Theo is five months old. We do not know about developmental outcomes at one year, five years, or beyond. The trial includes 12-month neurodevelopmental follow-up.
Replicability: Can other surgical teams achieve the same results? The trial does not answer this question — it is a single-arm feasibility study at one centre.
Scalability: Even if the trial succeeds, the infrastructure and expertise required to offer the procedure broadly do not currently exist. Building that capacity would take years.

Bottom Line

Three babies have now undergone in-utero repair of complex gastroschisis. All three have had outcomes that make the standard postnatal pathway — months in NICU, multiple surgeries, 10% mortality — look archaic by comparison. The evidence bar is not yet met. Three patients is not a trial. But the direction of travel is unmistakable. The womb is becoming an operating theatre, and the conditions that can be treated there are expanding. Gastroschisis may be the second condition — after spina bifida — to have its standard of care rewritten by fetal surgery. Cardiac and lung procedures are next on the list.

Sources:

BBC News, "Woman has pioneering womb surgery to fix 'miracle' baby with intestines outside its body," 3 August 2026 (Tier 1)
Great Ormond Street Hospital, "First UK baby receives pioneering surgery in the womb for rare bowel condition," 3 August 2026 (Tier 1 — official press release)
The Independent, "Baby boy becomes first UK child to have pioneering surgery for rare condition while still in womb," 3 August 2026 (Tier 2)
ClinicalTrials.gov, NCT05704257, "Fetal Repair of Complex Gastroschisis: A Safety and Feasibility Trial," Baylor College of Medicine (Tier 1 — primary source)